Cyllene Therapeutics is a French biotechnology business that is pioneering a novel approach termed pinpoint gene therapy.
Cyllene Therapeutics has raised $37.7M in total funding. The most recent round was Series C. The last funding was announced in July 2026.
Cyllene Therapeutics's investors include Lamond Ventures, Bpifrance, Andera Partners, GordonMD Global Investments, M Ventures.
Cyllene Therapeutics is headquartered in Paris, France.
Cyllene Therapeutics is a French biotechnology business that is pioneering a novel approach termed pinpoint gene therapy.
Cyllene Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cyllene Therapeutics — Funding & Investors." VCBacked, July 7, 2026, https://www.vcbacked.co/company/cyllene-therapeutics. Accessed September 20, 2026.
VCBacked. (2026). Cyllene Therapeutics — Funding & Investors. Retrieved September 20, 2026, from https://www.vcbacked.co/company/cyllene-therapeutics
{{cite web |title=Cyllene Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/cyllene-therapeutics |website=VCBacked |access-date=September 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated